. 2022 Nov 14;13:1039157. doi: 10.3389/fimmu.2022.1039157

Table 3.

Univariate and multivariate analyses of OS and CSS for different characteristics of oligometastatic NSCLC in each cohort.

	SEER Cohort							Single-Center Cohort
Characteristics	Univariate analysis (OS)		Multivariate analysis (OS)					Univariate analysis (OS)						Multivariate analysis (OS)
	HR (95% CI)	P	HR (95% CI)		P			HR (95% CI)		P			HR (95% CI)	P
Sex
Female	1.353 (1.098-1.666)	0.004*		1.311 (1.057-1.626)	0.014*		1.603 (1.237-2.077)			<0.001*		1.599 (1.225-2.088)		0.001*
Male	1.353 (1.098-1.666)	0.004*		1.311 (1.057-1.626)	0.014*		1.603 (1.237-2.077)			<0.001*		1.599 (1.225-2.088)		0.001*
T stage		0.002*			0.013*					0.016*				0.126
T1	Reference			Reference			Reference					Reference
T2	0.878 (0.632-1.219)	0.437		0.850 (0.602-1.202)	0.359		0.968 (0.640-1.465)			0.878		0.911 (0.599-1.385)		0.838
T3	1.120 (0.854-1.469)	0.414		1.234 (0.933-1.632)	0.140		1.041 (0.697-1.555)			0.844		0.989 (0.656-1.490)		0.827
T4	1.608 (1.199-2.158)	0.002		1.475 (1.080-2.015)	0.015		1.775 (1.113-2.830)			0.016		1.501 (0.929-2.425)		0.076
Unknown	1.693(0.535-5.361)	0.371		0.801(0.247-2.597)	0.711		2.006(0.706-5.698)			0.191		1.377(0.473-4.011)		0.558
N stage		0.001*			<0.001*		*			0.015*				0.014*
N0	Reference			Reference			Reference					Reference
N1	1.347(0.977-1.857)	0.069		1.692(1.211-2.363)	0.002		1.222(0.815-1.832)			0.331		1.333(0.887-2.004)		0.166
N2	1.389(1.084-1.779)	0.009		1.570(1.207-2.043)	0.001		0.979(0.705-1.360)			0.900		1.032(0.742-1.435)		0.853
N3	1.944(1.412-2.676)	<0.001		2.062(1.471-2.890)	<0.001		1.714(1.221-2.406)			0.002		1.780(1.266-2.501)		0.001
Unknown	1.255(0.711-2.216)	0.434		1.572(0.874-2.830)	0.131		1.834(0.748-4.501)			0.185		1.902(0.775-4.668)		0.161
Immunotherapy
No	0.797 (0.649-0.980)	0.031*	0.754 (0.609-0.932)		0.044*				0.693 (0.539-0.890)	0.004*		0.697 (0.542-0.896)		0.005*
Yes	0.797 (0.649-0.980)	0.031*							0.693 (0.539-0.890)
	Univariate analysis (CSS)		Multivariate analysis (CSS)						Univariate analysis (CSS)			Multivariate analysis (CSS)
	HR (95% CI)	P	HR (95% CI)		P				HR (95% CI)	P		HR (95% CI)		P
Sex
Female	1.363 (1.094-1.697)	0.006*	1.282 (1.020-1.610)			0.033*			1.519 (1.156-1.998)		0.003*	1.502 (1.143-1.976)			0.004*
Male	1.363 (1.094-1.697)	0.006*				0.033*					0.003*				0.004*
T stage		0.005*				0.030*					0.024*				0.170*
T1	Reference		Reference						Reference			Reference
T2	0.923(0.655-1.301)	0.647	0.884(0.618-1.264)			0.500			0.888(0.570-1.385)		0.601	0.825(0.526-1.294)			0.403
T3	1.154(0.867-1.537)	0.326	1.228(0.917-1.645)			0.168			1.080(0.705-1.654)		0.723	0.933(0.644-1.531)			0.974
T4	1.638(1.201-2.235)	0.002	1.414(1.019-1.962)			0.038			1.747(1.068-2.857)		0.026	1.438(0.867-2.386)			0.160
Unknown	0.636(0.088-4.581)	0.654	0.281(0.038-2.054)			0.221			1.405(0.427-4.626)		0.576	0.992(0.295-3.341)			0.990
N stage		0.001*				<0.001*					0.015*				0.014*
N0	Reference		Reference						Reference
N1	1.466(1.049-2.049)	0.025	1.825(1.289-2.583)			0.001			1.397(0.921-2.119)		0.116	1.496(0.984-2.274)			0.060
N2	1.539(1.188-1.995)	0.001	1.747(1.329-2.297)			<0.001			1.046(0.740-1.477)		0.800	1.097(0.775-1.552)			0.601
N3	1.905(1.347-2.693)	<0.001	1.981(1.376-2.851)			<0.001			1.600(1.111-2.304)		0.012	1.637(1.136-2.359)			0.008
Unknown	1.342(0.741-2.429)	0.332	1.649(0.894-3.043)			0.110			2.254(0.916-5.550)		0.077	2.329(0.945-5.738)			0.066
Immunotherapy
No	0.796 (0.642-0.987)	0.043*		0.743 (0.596-0.928)		0.009*			0.715 (0.548-0.932)		0.013*	0.725 (0.556-0.945)			0.018*
Yes	0.796 (0.642-0.987)

*p value is significant.